A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
This study is ongoing, but not recruiting participants.
Study NCT01169298
Information provided by Celgene Corporation
First Received on July 22, 2010.
Last Updated on September 19, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
